Ensuring commercialization success
Market access strategy
When to start planning
When do I start planning my marketing authorization and importation submissions to Health Canada?
When should I start planning for my pricing strategy and market access submissions?
Submission strategy and support
Who to meet with
Advisory boards comprised of payers, leading physicians and other key opinion leaders
Consultation with patient associations and advocacy groups in Canada
Preparatory meetings with review bodies and key clinicians as needed
Health Economics and Outcomes Research
We understand the importance that real-world evidence plays in market access success. Demonstrating the clinical and economic benefit of your product is vital to obtaining reimbursement. Our experienced team of health economists can help you with health economic modeling for submissions; publication and study development, including Observational, Willingness-to-Pay, Pay for Performance models and Burden of Illness studies; and Canadian adaptation of global economic models.
We have extensive experience building budget impact analyses (BIAs) for complex specialty products, including rare disease, oncology and immunology (including biosimilar) products; as well as medical device and diagnostics. Our BIA models are developed within established guidelines of individual public and private payers, and clearly articulate the incremental impact to the drug plan’s bottom-line.
Your questions, answered.
What should I consider when commercializing a pharmaceutical product in Canada?
- Market research and landscape assessment requirements
- Pricing strategy, including submission to public and private payers
- Hospital and regional health group planning
- Product listing negotiations
- Health economic modeling
- Publication and study development
- Budget impact analyses